Correction: Use of "biokitHSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA

As the competing interests for only the previous calendar year were included in the published article and it is journal policy to list competing interests for the previous five years, a full declaration of interests for the authors is now published. As the competing interests for only the previous calendar year were included in the published article [1] and it is journal policy to list competing interests for the previous five years, a full declaration of interests for the authors is as follows: During this time, Dr. Corey was a consultant to a company involved in developing an HSV vaccine (Antigenics). His role was to advise the company on what potential HSV proteins they should select for their peptide based vaccine. Dr. Corey has been the lead investigator of several trials that used HSV serologies as a critical component of the study. These trials have used either the University of Washington Western blot or the Focus assay followed by the University of Washington Western blot. All grant funds associated with these trials were paid to the University of Washington to support personnel and supplies associated with the work. Dr. Corey received no salary support from these funds. Dr. Corey is associated with a company which sponsors aninformational website that is available to anyone with internetaccess without charge [2]. The website was created as a publicservice to health care providers and the lay public. Dr. Coreywrites content appearing on the website. In the years 2002 to2004, Focus Technologies, as well as several private individualsand companies involved in HSV therapy provided funding tosupport development of new content as well as periodicallyrevise and maintain the website. Dr. Corey received compensa-tion for writing and revising content on the website which pro-vides information on the epidemiology, clinicalmanifestations, therapy and diagnosis of HSV infection. Hiseditorial responsibilities did not involve the area of HSV serol-ogy. References1. Morrow RA, Friedrich D, Meier A, Corey L: Use of "biokit HSV-2Rapid Assay" to improve the positive predictive value ofFocus HerpeSelect HSV-2 ELISA. BMC Infect Dis 2005, 5:84.2. Herpes Diagnosis [http://www.herpesdiagnosis.com] Pre-publication historyThe pre-publication history for this paper can be accessedhere: http://www.biomedcentral.com/1471-2334/7/11/prepubPublished: 7 March 2007BMC Infectious Diseases 2007, 7:11 doi:10.1186/1471-2334-7-11Received: 20 February 2007Accepted: 7 March 2007 This article is available from: http://www.biomedcentral.com/1471-2334/7/11© 2007 Morrow et al; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.